EA200600294A1 - [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении - Google Patents

[1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении

Info

Publication number
EA200600294A1
EA200600294A1 EA200600294A EA200600294A EA200600294A1 EA 200600294 A1 EA200600294 A1 EA 200600294A1 EA 200600294 A EA200600294 A EA 200600294A EA 200600294 A EA200600294 A EA 200600294A EA 200600294 A1 EA200600294 A1 EA 200600294A1
Authority
EA
Eurasian Patent Office
Prior art keywords
naftyridin
schizophrenia
treatment
related compounds
disorders
Prior art date
Application number
EA200600294A
Other languages
English (en)
Other versions
EA009645B1 (ru
Inventor
Джерри Кларк
Джэми Дэвис
Дэвид Фейвор
Лоррейн Фей
Ллойд Франклин
Кевин Хенегер
Дуглас Джонсон
Брайан Нихельсон
Лигун Оу
Джозеф Томас Рипайн
Майкл Уолтерс
Эндрю Дэвид Уайт
Чжицзянь Чжу
Original Assignee
Уорнер-Ламберт Компани Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34216117&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200600294(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Уорнер-Ламберт Компани Ллс filed Critical Уорнер-Ламберт Компани Ллс
Publication of EA200600294A1 publication Critical patent/EA200600294A1/ru
Publication of EA009645B1 publication Critical patent/EA009645B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

Настоящее изобретение относится к соединениям формулы 1где G, А, Z, Q, X, Y и Rи R- такие, как определенные в описании, содержащим их фармацевтическим композициям и их применению для лечения расстройств центральной нервной системы и других расстройств.
EA200600294A 2003-08-22 2004-08-13 [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении EA009645B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49737003P 2003-08-22 2003-08-22
PCT/IB2004/002665 WO2005019215A1 (en) 2003-08-22 2004-08-13 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

Publications (2)

Publication Number Publication Date
EA200600294A1 true EA200600294A1 (ru) 2006-08-25
EA009645B1 EA009645B1 (ru) 2008-02-28

Family

ID=34216117

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600294A EA009645B1 (ru) 2003-08-22 2004-08-13 [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении

Country Status (36)

Country Link
US (3) US7160888B2 (ru)
EP (1) EP1660497A1 (ru)
JP (1) JP4034811B2 (ru)
KR (2) KR100765668B1 (ru)
CN (1) CN100422181C (ru)
AP (1) AP2006003525A0 (ru)
AR (1) AR045386A1 (ru)
AU (1) AU2004266191B2 (ru)
BR (1) BRPI0413860A (ru)
CA (1) CA2538915C (ru)
CR (2) CR8254A (ru)
CU (1) CU23464B7 (ru)
EA (1) EA009645B1 (ru)
EC (1) ECSP066391A (ru)
GE (1) GEP20084447B (ru)
GT (1) GT200500007A (ru)
HK (1) HK1091815A1 (ru)
HN (1) HN2004000319A (ru)
IL (1) IL173439A0 (ru)
IS (1) IS8267A (ru)
MA (1) MA28003A1 (ru)
ME (1) MEP45308A (ru)
MX (1) MXPA06002070A (ru)
MY (1) MY140693A (ru)
NL (1) NL1026892C2 (ru)
NO (1) NO20060324L (ru)
NZ (1) NZ545078A (ru)
OA (1) OA13238A (ru)
PA (1) PA8609701A1 (ru)
PE (1) PE20051039A1 (ru)
RS (1) RS20060129A (ru)
TN (1) TNSN06063A1 (ru)
TW (1) TWI298327B (ru)
UA (1) UA82541C2 (ru)
WO (1) WO2005019215A1 (ru)
ZA (1) ZA200601526B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2809257C2 (ru) * 2018-11-22 2023-12-08 Ф. Хоффманн-Ля Рош Аг Новые гетероциклические соединения

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
DE60231507D1 (de) 2001-07-20 2010-07-01 Psychogenics Inc Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US7851629B2 (en) 2004-06-08 2010-12-14 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
MXPA06013941A (es) 2004-06-08 2007-12-10 Neurosearch Sweden Ab Fenilpiperidinas disustituidas, novedosas, como moduladores de la neurotransmision de dopamina y serotonina.
PL1773772T3 (pl) * 2004-06-08 2010-11-30 Nsab Filial Af Neurosearch Sweden Ab Sverige Nowe dwupodstawione fenylopiperydyny/piperazyny jako modulatory neurotransmisji dopaminy
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
FR2877005A1 (fr) * 2004-10-22 2006-04-28 Bioprojet Soc Civ Ile Nouveaux derives d'arylpiperazine
WO2006081289A2 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
WO2006090273A2 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
WO2006090272A1 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc Isoquinoline [1,8]naphthyridin-2-ones and related compounds for treatment of schizophrenia
EA200701856A1 (ru) * 2005-04-01 2008-02-28 Уорнер-Ламберт Компани Ллс Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
GEP20105053B (en) * 2005-04-08 2010-07-26 Pfizer Prod Inc Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
AR055203A1 (es) * 2005-08-31 2007-08-08 Otsuka Pharma Co Ltd Derivados de benzotiofeno con propiedades antipsicoticas
CA2624965A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k.alpha.
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
CA2627779A1 (en) * 2005-10-31 2007-05-10 Pfizer Products Inc. Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1h-[1,8]naphthyridin-2-one
US7935706B2 (en) 2006-02-23 2011-05-03 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
WO2007116265A1 (en) * 2006-03-31 2007-10-18 Pfizer Products Inc. Process for making a tetrahydro-pyridoazepin-8-one compound
AU2007254179B2 (en) 2006-05-18 2013-03-21 Pharmacyclics Llc Intracellular kinase inhibitors
ES2366489T3 (es) * 2006-09-15 2011-10-20 Pfizer Products Inc. Compuesto de pirido (2,3-d) piridinona y sus uso como inhibidores de pi3.
US20100093738A1 (en) * 2006-10-06 2010-04-15 Basf Se Fungicidal Compounds and Fungicidal Compositions
AR063302A1 (es) * 2006-10-13 2009-01-21 Otsuka Pharma Co Ltd Derivados de 4-benzo[b]tiofen-4-il-piperazin-1-il con accion antagonista del receptor 5-ht2a de serotonina y receptor de adrenalina alfa1 y agonista parcial del receptor d2, una composicion farmaceutica que lo comprende y un proceso para producirla.
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
WO2008084324A1 (en) * 2007-01-04 2008-07-17 Pfizer Products Inc. Naphthyridinone compound
JP4785881B2 (ja) * 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
CL2008001002A1 (es) 2007-04-11 2008-10-17 Actelion Pharmaceuticals Ltd Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
CN101754761B (zh) * 2007-05-21 2014-06-18 雷维瓦药品公司 基于喹啉酮的非典型抗精神病药的组合物、合成和使用方法
PA8781801A1 (es) * 2007-05-30 2009-01-23 Wyeth Corp Derivados heteroarilo antidepresivos de benzodioxanos heterociclo-fusionados
US7928111B2 (en) * 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
ES2380398T3 (es) 2007-12-18 2012-05-11 Actelion Pharmaceuticals Ltd. Derivados 5-aminociclilmetil-oxazolidin-2-ona
JP2011529090A (ja) 2008-07-28 2011-12-01 江蘇国華投資有限公司 アラルキルピペリジン（又はピペラジン）誘導体及びその統合失調症治療のための使用
ES2915065T3 (es) 2008-07-31 2022-06-20 Firmenich Incorporated Procedimientos para hacer potenciadores del sabor dulce
NZ593891A (en) 2008-12-12 2013-05-31 Actelion Pharmaceuticals Ltd 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives
KR101779137B1 (ko) * 2009-01-23 2017-09-18 다케다 야쿠힌 고교 가부시키가이샤 폴리(ａｄｐ-리보스)폴리머라제(ｐａｒｐ) 억제제
ES2605232T3 (es) * 2009-02-26 2017-03-13 Reviva Pharmaceuticals, Inc. Composiciones, síntesis y métodos de utilización de derivados de arilpiperazina
WO2010151689A1 (en) 2009-06-25 2010-12-29 Alkermes, Inc. Heterocyclic compounds for the treatment of neurological and psychological disorders
CA2766033C (en) * 2009-06-25 2016-09-20 Alkermes, Inc. Prodrugs of nh-acidic compounds
JP5857040B2 (ja) 2010-05-04 2016-02-10 アルカーメス ファーマ アイルランド リミテッド 酸化ラクタム化合物の合成方法
AU2011270701B2 (en) 2010-06-24 2015-05-14 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US9156822B2 (en) 2010-07-02 2015-10-13 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine D2 receptors
WO2012080284A2 (en) 2010-12-17 2012-06-21 F. Hoffmann-La Roche Ag Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
SI3156056T1 (sl) 2011-03-18 2024-03-29 Alkermes Pharma Ireland Limited Farmacevtski sestavki, ki obsegajo estre sorbitana
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
CA2856749A1 (en) 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
EP2790734B1 (en) 2011-12-15 2019-02-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
JP6333802B2 (ja) 2012-03-19 2018-05-30 アルカームス ファーマ アイルランド リミテッド ベンジルアルコールを含む医薬組成物
WO2013142202A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
NZ630643A (en) 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
US20130267552A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
JP6345651B2 (ja) * 2012-05-09 2018-06-20 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ヘテロアリール化合物及びその使用方法
CA2885196C (en) 2012-09-19 2021-06-22 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
RU2688233C2 (ru) 2014-03-20 2019-05-21 Алкермес Фарма Айэленд Лимитед Препараты арипипразола, имеющие повышенные скорости впрыска
CN104785295B (zh) * 2015-03-18 2018-03-06 杭州创培信息科技有限公司 一种高选择性多巴胺铂炭催化剂的制备方法
US9902703B2 (en) 2015-07-01 2018-02-27 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
LT3386511T (lt) 2015-12-10 2021-08-25 Ptc Therapeutics, Inc. Hantingtono ligos gydymo būdai
CN106242934A (zh) * 2016-07-26 2016-12-21 云南民族大学 一种酮的β‑位C‑H键乙酰氧化合成方法
MX2019014514A (es) * 2017-06-05 2020-07-20 Ptc Therapeutics Inc Compuestos para tratar la enfermedad de huntington.
CA3067591A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
EP3645121A4 (en) 2017-06-28 2021-03-17 PTC Therapeutics, Inc. HUNTINGTON'S DISEASE TREATMENT METHODS
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
US20210017174A1 (en) 2018-03-07 2021-01-21 Bayer Aktiengesellschaft Identification and use of erk5 inhibitor
EA202092001A1 (ru) 2018-03-27 2021-01-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения болезни гентингтона
US11858941B2 (en) 2018-06-27 2024-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating Huntington's disease
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
WO2020033420A1 (en) 2018-08-07 2020-02-13 Firmenich Incorporated 5-substituted 4-amino-1h-benzo[c][1,2,6]thiadiazine 2,2-dioxides and formulations and uses thereof
CN112867720A (zh) * 2018-08-13 2021-05-28 豪夫迈·罗氏有限公司 作为单酰基甘油脂肪酶抑制剂的新型杂环化合物
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
JP2023509260A (ja) 2019-08-14 2023-03-08 インサイト・コーポレイション Ｃｄｋ２阻害剤としてのイミダゾリルピリミジニルアミン化合物
EP4028403B1 (en) 2019-09-12 2023-11-22 F. Hoffmann-La Roche AG 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
CN115298177A (zh) 2019-10-11 2022-11-04 因赛特公司 作为cdk2抑制剂的双环胺
CN114634479A (zh) * 2020-12-16 2022-06-17 北京盈科瑞创新药物研究有限公司 一种派嗪衍生物、其制备方法及应用
WO2022212538A1 (en) * 2021-03-31 2022-10-06 Blueprint Medicines Corporation Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof
WO2023186023A1 (zh) * 2022-03-30 2023-10-05 苏州旺山旺水生物医药股份有限公司 一类n-取代的喹啉酮化合物、其制备方法和用途
CN114805081A (zh) * 2022-05-20 2022-07-29 都创(上海)医药开发有限公司 一种基于微通道连续流技术快速制备1-萘胺的方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5649361A (en) 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
JPH07165720A (ja) * 1988-10-31 1995-06-27 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤
WO1990006303A1 (en) 1988-12-02 1990-06-14 Pfizer Inc. Arylpiperidine derivatives
DK0402644T3 (da) 1989-05-19 1996-01-02 Hoechst Roussel Pharma N-(Aryloxyalkyl)-heteroarylpiperidiner og -heteroarylpiperaziner, fremgangsmåde til deres fremstilli ng samt deres anvendelse som medikamenter
US5350747A (en) * 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
WO1991000863A1 (en) * 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
US5032598A (en) 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
IL101722A (en) * 1991-05-02 1996-05-14 Wyeth John & Brother Ltd History of piperazine, their preparation and pharmaceutical preparations containing them
NZ240863A (en) 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
JP2781661B2 (ja) 1992-12-17 1998-07-30 フアイザー・インコーポレイテツド Ｃｒｆアンタゴニストとしての置換ピラゾール
US6765008B1 (en) 1992-12-17 2004-07-20 Pfizer Inc Pyrrolopyrimidines as CRF antagonists
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
CZ284157B6 (cs) 1992-12-17 1998-08-12 Pfizer Inc. Pyrazolové a pyrazolopyrimidinové sloučeniny jako takové a pro léčbu chorob a farmaceutické prostředky na jejich bázi
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
FR2699918B1 (fr) * 1992-12-30 1995-03-17 Pf Medicament Ligands sélectifs des récepteurs 5HY1D-5HT1B dérivés d'indole-pipérazine utiles comme médicaments.
JPH07247271A (ja) * 1994-01-21 1995-09-26 Otsuka Pharmaceut Co Ltd ３，４−ジヒドロカルボスチリル誘導体
FR2731222A1 (fr) 1995-03-02 1996-09-06 Pf Medicament Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments
JP2900130B2 (ja) * 1995-03-16 1999-06-02 大塚製薬株式会社 カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤
JP2987484B2 (ja) * 1995-03-16 1999-12-06 大塚製薬 株式会社 カルボスチリル誘導体の製造方法
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
AU6517196A (en) 1995-07-13 1997-02-10 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
WO1997014419A1 (en) 1995-10-20 1997-04-24 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
JPH09241161A (ja) 1996-03-08 1997-09-16 Nippon Shinyaku Co Ltd 医 薬
US5912256A (en) 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
US6498163B1 (en) 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
FR2761071B1 (fr) 1997-03-20 1999-12-03 Synthelabo Derives de quinolein-2(1h)-one et de dihydroquinolein-2(1h)- one, leur preparation et leur application en therapeutique
FR2769912B1 (fr) 1997-10-16 2000-03-10 Pf Medicament Nouveaux derives de la 3-oxo- (2h)-1,2,4 triazine leur preparation et leur application en therapeutique humaine
DE19747063A1 (de) * 1997-10-24 1999-04-29 Basf Ag 3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung
US6267784B1 (en) 1998-05-01 2001-07-31 Benz Research And Development Corporation Intraocular lens and haptics made of a copolymer
EP1246822A1 (en) 1999-12-20 2002-10-09 Eli Lilly And Company Benzofuran derivatives
DE10041574A1 (de) 2000-08-24 2002-03-07 Merck Patent Gmbh Chromenonderivate
WO2002048105A2 (en) 2000-11-16 2002-06-20 Wyeth Aryloxy piperidinyl derivatives for the treatment of depression
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
AR032641A1 (es) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
CZ2004156A3 (cs) 2001-06-29 2004-05-12 H@Álundbeckáa@S Název neuveden
GB0227240D0 (en) 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
TW200507841A (en) 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2809257C2 (ru) * 2018-11-22 2023-12-08 Ф. Хоффманн-Ля Рош Аг Новые гетероциклические соединения

Also Published As

Publication number Publication date
CA2538915C (en) 2010-06-15
US20050043309A1 (en) 2005-02-24
ZA200601526B (en) 2007-04-25
US7160888B2 (en) 2007-01-09
EA009645B1 (ru) 2008-02-28
KR100765668B1 (ko) 2007-10-10
WO2005019215A1 (en) 2005-03-03
MXPA06002070A (es) 2006-05-19
KR100801794B1 (ko) 2008-02-05
RS20060129A (en) 2008-06-05
CA2538915A1 (en) 2005-03-03
KR20060071404A (ko) 2006-06-26
PE20051039A1 (es) 2005-12-12
ECSP066391A (es) 2006-08-30
AU2004266191A1 (en) 2005-03-03
IL173439A0 (en) 2006-06-11
TWI298327B (en) 2008-07-01
CR8254A (es) 2006-10-17
US20060287310A1 (en) 2006-12-21
AR045386A1 (es) 2005-10-26
CU23464B7 (es) 2009-12-17
GT200500007A (es) 2005-10-24
OA13238A (en) 2006-12-13
MY140693A (en) 2010-01-15
PA8609701A1 (es) 2005-05-24
UA82541C2 (ru) 2008-04-25
US20060287309A1 (en) 2006-12-21
NZ545078A (en) 2009-09-25
JP2007503386A (ja) 2007-02-22
NL1026892A1 (nl) 2005-02-28
TNSN06063A1 (en) 2007-10-03
AU2004266191B2 (en) 2009-11-26
KR20070053364A (ko) 2007-05-23
TW200524938A (en) 2005-08-01
MA28003A1 (fr) 2006-07-03
BRPI0413860A (pt) 2006-10-24
HK1091815A1 (en) 2007-01-26
CN1839134A (zh) 2006-09-27
IS8267A (is) 2006-01-26
MEP45308A (en) 2011-02-10
EP1660497A1 (en) 2006-05-31
HN2004000319A (es) 2010-06-09
GEP20084447B (en) 2008-08-10
CN100422181C (zh) 2008-10-01
CR9834A (es) 2008-04-21
JP4034811B2 (ja) 2008-01-16
NL1026892C2 (nl) 2005-11-21
NO20060324L (no) 2006-05-18
AP2006003525A0 (en) 2006-02-28

Similar Documents

Publication Publication Date Title
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
EA200200716A1 (ru) Арилконденсированные азаполициклические соединения
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
EA200601239A1 (ru) Замещённые хинолиновые соединения
NZ539841A (en) Hydroxyethylamine derivatives for the treatment of alzheimer's disease
EA200600892A1 (ru) Новые хинолиновые производные
ATE363473T1 (de) Substituierte pyrazoloverbindungen zur behandlung von entzündungen
DE60132309D1 (de) Amin-derivate zur behandlung von apoptosis
ATE457027T1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on- verbindungen zur behandlung von fettsucht
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
EA200401114A2 (ru) Замещённые гидроксиэтиламины
BRPI0411294A (pt) derivados de amino-propanol
TW200502221A (en) Novel lactams and uses thereof
EP1689713A4 (en) BENZYLETHER AND BETA-SECRETASE BENZYLAMINO INHIBITORS FOR TREATING ALZHEIMER'S DISEASE
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
BRPI0416030A (pt) pirido-7-pirimidin-7-onas substituìdas com hidroxialquila
BG108180A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
EA200701856A1 (ru) Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
EA200100516A1 (ru) Производные 3,3-биарилпиперидина и 2,2-биарилморфолина
SE9903894D0 (sv) Novel compounds
MXPA05004273A (es) Derivados de fenilalquil y piridilalquil piperazina.
EA200600777A1 (ru) N-замещённые пиразолилкарбоксанилиды

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU